Regulator Or Enabler? Germany's Paul Ehrlich Institute And The Pfizer-BioNTech Vaccine

Two of the slides used by German chemistry professors Gerald Dyker and Jörg Matysik in their now famous interview on the variable toxicity of different batches of the Pfizer-BioNTech vaccine have been seen around the world: the graph from the Danish study, showing enormous differences in toxicity between 'blue,' 'green,' and 'yellow' batches, and their own table displaying an almost solid column of 'neins,' indicating that the responsible regulator, Germany's Paul Ehrlich Institute, did not subject the apparently harmless 'yellow' batches to quality control testing.

The third slide from the interview also deserves to be better known, since it refocuses attention on a crucial aspect of this story which has been almost completely obscured amidst the sound and fury of the attempted "Debunkings" of the placebo hypothesis: namely, the relationship between the regulator, the Paul Ehrlich Institute, and the manufacturer, Germany's BioNTech.

It is the German firm BioNTech which was responsible for providing batch samples to the German regulator, the Paul Ehrlich Institute, as Dyker and Matysik's interview likewise makes clear.

Prof. Klaus Cichutek and I are in the room in which the efficacy of the BioNTech vaccine is tested.

In the interview, Prof. Dyker expresses his and his colleagues' puzzlement about Lauterbach's assertion that the efficacy of the BioNTech vaccine is tested at the PEI: 'We have never heard of there being any kind of rapid test of the efficacy of vaccines,' he says, 'Normally, that is tested in a clinical trial, after all.

In fact we know that there was precisely compromising on safety: not only because of the horrendous safety data associated with the blue batches of the vaccine - which, perhaps not coincidentally, appear to have been the earliest batches released in the EU - but also because the shortcuts taken by BioNTech with the PEI's blessing are a matter of public record.

In collaboration with BioNTech and the biopharmaceutical research institute Translational Oncology at the University of Mainz, the DZIF is researching RNA-based vaccines for selected virus families with potential human pathogens, and subsequently bringing them into preclinical and early clinical development. 

https://brownstone.org/articles/regulator-or-enabler-paul-ehrlich-institute-pfizer-biontech-vaccine/